The Costs Associated with Healthcare Resource Use and Work Productivity for Care Partners of Multiple Myeloma Patients in the United States and Europe
Author(s)
Kathy Annunziata, MA1, Nikoletta Sternbach, BA1, Hitomi Tanaka, BS2, Marco DiBonaventura, PhD2, Joseph C. Cappelleri, MPH, MS, PhD3, Jack Watkins, PharmD2, David Hughes, PharmD4, Aster Meche, MPH2, Chai Hyun Kim, BA2, C. Todd Kennedy, CMCE5, Thomas Leblanc, PhD6, Patrick Hlavacek, MPH7.
1Oracle Life Science, Austin, TX, USA, 2Pfizer Inc, New York, NY, USA, 3Pfizer Inc, Groton, CT, USA, 4Pfizer Inc, Cambridge, MA, USA, 5Independent research and patient advocate, Coto De Caza, CA, USA, 6Duke University School of Medicine, Division of Hematological Malignancies and Cellular Therapy, Durham, NC, USA, 7Pfizer, New York, NY, USA.
1Oracle Life Science, Austin, TX, USA, 2Pfizer Inc, New York, NY, USA, 3Pfizer Inc, Groton, CT, USA, 4Pfizer Inc, Cambridge, MA, USA, 5Independent research and patient advocate, Coto De Caza, CA, USA, 6Duke University School of Medicine, Division of Hematological Malignancies and Cellular Therapy, Durham, NC, USA, 7Pfizer, New York, NY, USA.
Presentation Documents
OBJECTIVES: The impact on quality of life to care partners of patients living with multiple myeloma (MM) can be significant; however, there can also be a significant economic burden. This study sought to quantify the costs associated with healthcare resource use (HCRU) and lost work productivity for care partners of MM patients in the United States and Europe.
METHODS: The 2021/2022 National Health and Wellness Survey (NHWS) served as the data source. The NHWS is an online, cross-sectional, population-based health survey conducted in the US (N=75,261) and European Union 4 (EU4; France, Germany, Italy, Spain)+United Kingdom (UK; N=62,028). Survey questions assessed demographics and health history (including whether a respondent provides care to an adult relative with MM; “care partners”). Separately for each region (US and EU4+UK), care partners were compared 1:1 to country-, age-, sex-, and comorbidity-matched non-care partner controls on work productivity (Work Productivity and Activity Impairment-General Health [WPAI-GH] questionnaire) and self-reported HCRU. Country-specific average wage rates and HCRU unit costs were used to estimate per-person, per-year (PPPY) direct (hospitalization, emergency room, and physician visit costs) and indirect (total missed/impaired work) costs. Results were reported descriptively.
RESULTS: N=105 and 70 care partners were identified in the US and EU4+UK, respectively (mean age = 39.1 and 36.9 years, 58.1% and 65.7% male, 57.1% and 32.9% had a university degree). Compared with matched controls, PPPY direct healthcare costs were much higher among care partners (US: $119,904 vs $7,270; EU4+UK: €25,273 vs €3,865), driven by higher hospitalization rates. Similarly, total PPPY indirect costs (due to lost wages) were also much higher for care partners (US: $48,604 vs $13,894; EU4+UK: €14,257 vs €5,928).
CONCLUSIONS: Care partners to patients living with MM experience significant direct and indirect costs in both the US and Europe.
METHODS: The 2021/2022 National Health and Wellness Survey (NHWS) served as the data source. The NHWS is an online, cross-sectional, population-based health survey conducted in the US (N=75,261) and European Union 4 (EU4; France, Germany, Italy, Spain)+United Kingdom (UK; N=62,028). Survey questions assessed demographics and health history (including whether a respondent provides care to an adult relative with MM; “care partners”). Separately for each region (US and EU4+UK), care partners were compared 1:1 to country-, age-, sex-, and comorbidity-matched non-care partner controls on work productivity (Work Productivity and Activity Impairment-General Health [WPAI-GH] questionnaire) and self-reported HCRU. Country-specific average wage rates and HCRU unit costs were used to estimate per-person, per-year (PPPY) direct (hospitalization, emergency room, and physician visit costs) and indirect (total missed/impaired work) costs. Results were reported descriptively.
RESULTS: N=105 and 70 care partners were identified in the US and EU4+UK, respectively (mean age = 39.1 and 36.9 years, 58.1% and 65.7% male, 57.1% and 32.9% had a university degree). Compared with matched controls, PPPY direct healthcare costs were much higher among care partners (US: $119,904 vs $7,270; EU4+UK: €25,273 vs €3,865), driven by higher hospitalization rates. Similarly, total PPPY indirect costs (due to lost wages) were also much higher for care partners (US: $48,604 vs $13,894; EU4+UK: €14,257 vs €5,928).
CONCLUSIONS: Care partners to patients living with MM experience significant direct and indirect costs in both the US and Europe.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE370
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology